Press Release **For Immediate Release**

Glenmark Pharmaceuticals receives tentative ANDA approval for Rufinamide Tablets USP

Mumbai, May 21, 2015: Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted tentative approval last week by the United States Food & Drug Administration (U.S. FDA) for its Rufinamide Tablets USP, 200 mg and 400 mg, a therapeutic equivalent of Banzel® Tablets of Eisai, Inc. Under the terms of a settlement agreement between Glenmark and Eisai, Glenmark will be permitted to market this product in the United States on May 30, 2022 or potentially earlier under certain circumstances.

According to IMS Health sales data for the 12 month period ending March 2015, the Banzel® market achieved annual sales of approximately $121.8 million.

Glenmark's current portfolio consists of 96 products authorized for distribution in the U.S. marketplace and 68 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

About Glenmark Pharmaceuticals:

Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical company headquartered at Mumbai, India. It is ranked among the top 80 Pharma& Biotech companies of the world in terms of revenues. (SCRIP 100 Rankings published in the year 2014). Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). Glenmark has several molecules in various stages of clinical development and is primarily focused in the areas of Inflammation [asthma/COPD, rheumatoid arthritis etc.] and Pain [neuropathic pain and inflammatory pain]. The company has a significant presence in branded generics markets across emerging economies including India. GPL along with its subsidiary has 14 manufacturing facilities in four countries and has six R&D centers.

For further information, please contact:

Jason D'Souza / Rajdeep Barooah
Glenmark, Mumbai, India Tel: [+91 22] 40189919/984
Email: corpcomm@glenmarkpharma.com